Biophytis Gets EMA Green Light for COVID-19 Trial
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, covid-19
TL;DR
Biophytis SA just got EMA approval to start their Phase 2/3 COVID-19 trial in Europe, first patient next month!
AI Summary
On September 2, 2025, Biophytis S.A. announced it received EMA authorization for its Investigational Medicinal Product (IMP) for the treatment of severe COVID-19 patients. This authorization allows Biophytis to initiate its Phase 2/3 clinical trial, COVA-2, in Europe, with the first patient expected to be enrolled in September 2025.
Why It Matters
This EMA authorization is a critical step for Biophytis, enabling them to proceed with a significant clinical trial for a severe COVID-19 treatment, potentially impacting future patient care.
Risk Assessment
Risk Level: medium — Clinical trial authorizations are positive but success is not guaranteed, and regulatory hurdles can still arise.
Key Numbers
- Phase 2/3 — Clinical Trial Phase (COVA-2 trial for severe COVID-19)
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Stanislas Veillet (person) — Contact Person
- European Medicines Agency (EMA) (company) — Regulatory Body
- September 2, 2025 (date) — Press Release Date
- September 2025 (date) — Expected Patient Enrollment
FAQ
What is the name of the clinical trial Biophytis S.A. is initiating?
The clinical trial is named COVA-2.
What specific authorization did Biophytis S.A. receive?
Biophytis S.A. obtained EMA authorization for its Investigational Medicinal Product (IMP).
What condition is the IMP intended to treat?
The IMP is intended for the treatment of severe COVID-19 patients.
In which region can Biophytis S.A. now initiate its clinical trial?
Biophytis S.A. can now initiate its clinical trial in Europe.
When is the first patient expected to be enrolled in the COVA-2 trial?
The first patient is expected to be enrolled in September 2025.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-09-03 10:53:28
Filing Documents
- tm2525134d1_6k.htm (6-K) — 10KB
- tm2525134d1_ex99-1.htm (EX-99.1) — 10KB
- tm2525134d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-25-086790.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOPHYTIS S.A. Date: September 3, 2025 By: /s/ Stanislas Veillet Name: Stanislas Veillet Title: Chairman and Chief Executive Officer